Assessment of caspofungin susceptibility of Candida glabrata by the Etest®, CLSI, and EUCAST methods, and detection of FKS1 and FKS2 mutations

Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?

(2013) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

(2013) Barbara D. Alexander et al.   CLINICAL INFECTIOUS DISEASES

Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme

(2013) M.C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

Echinocandin Resistance in Candida Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches

(2012) Nicholas D Beyda et al.   ANNALS OF PHARMACOTHERAPY

Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin Breakpoints

(2012) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Recurrent Episodes of Candidemia Due to Candida glabrata with a Mutation in Hot Spot 1 of theFKS2Gene Developed after Prolonged Therapy with Caspofungin

(2012) María Teresa Durán-Valle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

(2012) O.A. Cornely et al.   CLINICAL MICROBIOLOGY AND INFECTION

Echinocandin Susceptibility Testing ofCandidaspp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots

(2011) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009)

(2011) Michael A. Pfaller et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients

(2010) Olivier Lortholary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance

(2010) A. J. Zimbeck et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species

(2010) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts

(2008) J.L. Rodriguez-Tudela et al.   CLINICAL MICROBIOLOGY AND INFECTION